CanSino looks for next growth shot in ‘life after Covid’
The vaccine maker is back to square one as a brief windfall fueled by demand for its Covid vaccines rapidly fades Key Takeaways: CanSino logged sizable asset impairments for its…
Recent Articles
CanSino looks for next growth shot in ‘life after Covid’
6185.HK
688185.SHG
RELATED ARTICLES
-
Dispute over Covid vaccines casts doubt on Clover Bio recovery
2197.HK -
Zhengye Biotech’s ‘pet-sized’ IPO leaves plenty of room for more fundraising
ZYBT.US
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
WuXi Biologics sells vaccine plant as new U.S. law looms
2269.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Noah’s development arc takes overseas turn as life at home only gets tougher
6686.HK NOAH.US
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
